Consolidated Statement of Cash Flows (USD $)	6 Months Ended		59 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2011
Operating activities:
Net loss	$ (801,933)	$ (1,980,854)	$ (17,471,596)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	24,719	10,456	75,429
Warrants issued in connection with convertible notes payable	0	0	49,245
Amortization of convertible loan discount	83,396	0	404,858
Common stock issued for services	81,713	1,503,987	11,612,314
Stock option compensation	0	0	307,512
Warrants issued for services	0	46,735	337,359
Change in value of derivatives	(3,536)	0	15,661
Equipment write-down	0	0	5,399
Patent write-down	21,758	0	35,258
Effect of changes in:
Inventory	(32,957)	0	(86,013)
Prepaid expenses and other current assets	1,175	2,570	(2,162)
Advances to related parties	(25,560)	0	(25,560)
Deposits	0	0	(9,500)
Bank overdraft, net	0	10,280	0
Accounts payable and accrued expenses	72,408	32,513	269,802
Accrued payroll	302,029	(3,635)	730,266
Advances	0	67,896	36,533
Deferred revenue	100,000	(33,811)	116,951
Net cash used in operating activities	(176,788)	(343,863)	(3,598,244)
Investing activities:
Purchase of property and equipment	(9,343)	0	(108,535)
Payments for systems	0	(132,898)	(152,721)
Payments for patents	(16,878)	0	(151,490)
Net cash used in investing activities	(26,221)	(132,898)	(412,746)
Financing activities:
Proceeds from (payments on) bank loan borrowings	(103,839)	(25,990)	382,271
Proceeds from sales of preferred stock	0	0	725,000
Proceeds from convertible notes payable	132,500	0	518,712
Payments on convertible notes payable	(47,500)	0	(102,500)
Proceeds from sale of common stock	35,000	324,641	2,139,688
Payments on related-party short-term loans	(15,750)	0	(15,750)
Proceeds from related-party short-term loans	0	0	15,750
Proceeds from short-term loans	100,000	187,025	284,000
Advances	100,000	0	100,000
Payments of short-term loans	0	(9,000)	(24,000)
Net cash provided by financing activities	200,411	476,676	4,023,171
Net increase in cash	(2,598)	(85)	12,181
Cash, beginning of period	14,779	270	0
Cash, end of period	12,181	185	12,181
Supplemental disclosures of cash flow information:
Cash paid for interest	39,056	16,248	232,648
Cash paid for income taxes	1,600	1,600	8,328
Supplemental disclosure of non-cash investing and financing activities:
Warrants issued in connection with preferred stock	0	0	155,714
Beneficial conversion feature on preferred stock	0	0	11,111
Conversion of preferred to common shares in reverse merger	0	0	625,000
Proceeds from sales of preferred shares used to purchase shares of Bio	0	0	400,000
Conversion of note payable to common stock	0	0	278,922
Conversion of short-term loan to common stock	0	0	100,000
Accrued dividends issued to preferred stockholders	3,000	3,000	16,733
Conversion of convertible notes payable and accrued interest to common stock	$ 76,044	$ 0	$ 297,690